Allworth Financial’s Taysha Gene Therapies TSHA Stock Holding History

Allworth Financial’s Portfolio TSHA Stock Details TSHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.5K	Buy	6,978 +1,535	+28%	+$9.08K	﹤0.01%	2535
2026 Q1	$24.3K	Buy	5,443 +5,220	+2,341%	+$24.3K	﹤0.01%	2849
2025 Q4	$1.23K	Buy	223 +8	+4%	+$39	﹤0.01%	4300
2025 Q3	$704	Buy	+215	New	+$609	﹤0.01%	4354
2025 Q2	–	Sell	-1,000	Closed	-$1.82K	–	4672
2025 Q1	$1.82K	Hold	1,000	–	–	﹤0.01%	3244
2024 Q4	$1.53K	Hold	1,000	–	–	﹤0.01%	3250
2024 Q3	$2.01K	Hold	1,000	–	–	﹤0.01%	2970
2024 Q2	$2.14K	Hold	1,000	–	–	﹤0.01%	2893
2024 Q1	$2.87K	Hold	1,000	–	–	﹤0.01%	2663
2023 Q4	$1.77K	Hold	1,000	–	–	﹤0.01%	2723
2023 Q3	$3.16K	Hold	1,000	–	–	﹤0.01%	2331
2023 Q2	$661	Hold	1,000	–	–	﹤0.01%	2840
2023 Q1	$798	Hold	1,000	–	–	﹤0.01%	2749
2022 Q4	$2.26K	Hold	1,000	–	–	﹤0.01%	2199
2022 Q3	$2K	Hold	1,000	–	–	﹤0.01%	2237
2022 Q2	$4K	Buy	+1,000	New	+$3.97K	﹤0.01%	1846

Other funds holding TSHA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Allworth Financial's TSHA Position: Q2 2026 in Review

Allworth Financial increased its Taysha Gene Therapies (TSHA) stake by 28% in Q2 2026, buying an estimated $9.08K and bringing the position to 6,978 shares worth $47.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2535.

Allworth Financial first reported a position in TSHA in Q2 2022 and has held it in 16 quarters since. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

Allworth Financial held 6,978 shares of Taysha Gene Therapies worth $47.5K as of Q2 2026.
Allworth Financial bought 1,535 Taysha Gene Therapies shares in Q2 2026, an estimated $9.08K.
Taysha Gene Therapies made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #2535 holding.
Allworth Financial first reported a position in Taysha Gene Therapies in Q2 2022 and has held it in 16 quarters since.
208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.